These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 8604621)

  • 41. Increased platelet responsiveness following coronary stenting. Heparin as a possible aetiological factor in stent thrombosis.
    Knight CJ; Panesar M; Wilson DJ; Patrineli A; Chronos N; Wright C; Clarke D; Patel D; Fox K; Goodall AH
    Eur Heart J; 1998 Aug; 19(8):1239-48. PubMed ID: 9740346
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Excess dosing of antithrombotic therapy in non-ST-segment elevation acute coronary syndromes.
    Yan AT; Yan RT; Goodman SG
    JAMA; 2006 Apr; 295(16):1896; author reply 1897. PubMed ID: 16639044
    [No Abstract]   [Full Text] [Related]  

  • 43. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty.
    Topol EJ; Bonan R; Jewitt D; Sigwart U; Kakkar VV; Rothman M; de Bono D; Ferguson J; Willerson JT; Strony J
    Circulation; 1993 May; 87(5):1622-9. PubMed ID: 8491018
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of clopidogrel on the rebound hypercoagulable state after heparin discontinuation in patients with acute coronary syndromes.
    Di Nisio M; Bijsterveld NR; Meijers JC; Levi M; Büller HR; Peters RJ
    J Am Coll Cardiol; 2005 Oct; 46(8):1582-3. PubMed ID: 16226189
    [No Abstract]   [Full Text] [Related]  

  • 45. Relation between abrupt vessel closure and the anticoagulant response to heparin or bivalirudin during coronary angioplasty.
    Bittl JA; Ahmed WH
    Am J Cardiol; 1998 Oct; 82(8B):50P-56P. PubMed ID: 9809892
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bivalirudin: a review of its potential place in the management of acute coronary syndromes.
    Carswell CI; Plosker GL
    Drugs; 2002; 62(5):841-70. PubMed ID: 11929334
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Weight-based protocol for improving heparin therapy.
    Nemeth JS; Marxen TL; Piltz GW
    Am J Health Syst Pharm; 1996 May; 53(10):1164-6. PubMed ID: 8734678
    [No Abstract]   [Full Text] [Related]  

  • 48. Bleeding risk and outcomes of Bivalirudin versus Glycoprotein IIb/IIIa inhibitors with targeted low-dose unfractionated Heparin in patients having percutaneous coronary intervention for either stable or unstable angina pectoris.
    Steinberg DH; Shah P; Kinnaird T; Pinto Slottow TL; Roy PK; Okabe T; Bonello L; de Labriolle A; Smith KA; Torguson R; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
    Am J Cardiol; 2008 Jul; 102(2):160-4. PubMed ID: 18602514
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antithrombin-III plasma activity during and after prolonged use of heparin in unstable angina.
    Lidón RM; Théroux P; Robitaille D
    Thromb Res; 1993 Oct; 72(1):23-32. PubMed ID: 8122184
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction angina. Hirulog Angioplasty Study Investigators.
    Bittl JA; Feit F
    Am J Cardiol; 1998 Oct; 82(8B):43P-49P. PubMed ID: 9809891
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Argatroban for elective percutaneous coronary intervention: the ARG-E04 multi-center study.
    Rössig L; Genth-Zotz S; Rau M; Heyndrickx GR; Schneider T; Gulba DC; Desaga M; Buerke M; Harder S; Zeiher AM;
    Int J Cardiol; 2011 Apr; 148(2):214-9. PubMed ID: 20226548
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The use of low molecular weight heparin to predict clinical outcome in patients with unstable angina that had undergone percutaneous coronary intervention.
    Hong YJ; Jeong MH; Lee SH; Park OY; Kim JH; Kim W; Rhew JY; Ahn YK; Cho JG; Park JC; Suh SP; Ahn BH; Kim SH; Kang JC
    Korean J Intern Med; 2003 Sep; 18(3):167-73. PubMed ID: 14619386
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bivalirudin for patients with acute coronary syndromes.
    Stone GW; McLaurin BT; Cox DA; Bertrand ME; Lincoff AM; Moses JW; White HD; Pocock SJ; Ware JH; Feit F; Colombo A; Aylward PE; Cequier AR; Darius H; Desmet W; Ebrahimi R; Hamon M; Rasmussen LH; Rupprecht HJ; Hoekstra J; Mehran R; Ohman EM;
    N Engl J Med; 2006 Nov; 355(21):2203-16. PubMed ID: 17124018
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Heparin-induced thrombosis with a normal platelet count.
    Alvarez GF; Bihari D; Collins D
    Crit Care Resusc; 2007 Mar; 9(1):51-3. PubMed ID: 17352667
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Heparin is more effective than inogatran, a low-molecular weight thrombin inhibitor in suppressing ischemia and recurrent angina in unstable coronary disease. Thrombin Inhibition in Myocardial Ischemia (TRIM) Study Group.
    Andersen K; Dellborg M
    Am J Cardiol; 1998 Apr; 81(8):939-44. PubMed ID: 9576150
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Massive intracavitary clot formation during cardiopulmonary bypass.
    Legare JF; Arora R; Wood JW
    Can J Cardiol; 2004 Jun; 20(8):825-6. PubMed ID: 15229767
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preprocedural anticoagulation does not reduce angioplasty heparin requirements.
    Blumenthal RS; Wolff MR; Resar JR; Coombs VJ; Brinker JA
    Am Heart J; 1993 May; 125(5 Pt 1):1221-5. PubMed ID: 8480572
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty.
    McGarry TF; Gottlieb RS; Morganroth J; Zelenkofske SL; Kasparian H; Duca PR; Lester RM; Kreulen TH
    Am Heart J; 1992 Jun; 123(6):1445-51. PubMed ID: 1595522
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Increased thrombin activity correlates with increased ischemic event rate after percutaneous transluminal coronary angioplasty: lack of efficacy of locally delivered urokinase.
    Wilensky RL; Pyles JM; Fineberg N
    Am Heart J; 1999 Aug; 138(2 Pt 1):319-25. PubMed ID: 10426846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.